The place of cyclosporin in the management of primary nephrotic syndrome

BioDrugs

Volumn 12, Issue 5, 1999, Pages 327-341

  Ponticelli, Claudio ^a   Passerini, Patrizia ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC AGENT;

DRUG EFFICACY; DRUG TOLERABILITY; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; HYPERTRICHOSIS; KIDNEY FUNCTION; MUSCLE CRAMP; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0032747225     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912050-00002     Document Type: Review

References (117)

1. Borel JF. Mechanism of action of cyclosporin A and rationale use in nephrotic syndrome. Clin Nephrol 1991; 35 Suppl. 1: S23-30
2. Ponticelli C. Glucocorticoids and immunomodulating agents. In: Ponticelli C, Glassock RJ, editors. Treatment of primary glomerulonephritis. New YorK; Oxford University Press, 1997: 25-77
3. Ferracioli G, Guerra P, Rizzi V, et al. Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases. J Rheumatol 1995; 22: 1060-4
4. Kruger K, Schattenkircher M. Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis - results of a double-blind multicentre study. Clin Rheumatol 1994; 13: 248-55
5. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Dermatology 1993; 187: 8-18
6. Jewell P, Lennard-Jones JE, The Cyclosporin Study Group Of Great-Britain, Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 439-50
7. De Vries J, Baarsma GS, Zaal MJW, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophtalmol 1990; 74: 344-9
8. Favre H, Miescher PA, Huang YP, et al. Cyclosporin in the treatment of lupus nephritis. Am J Nephrol 1989; 9: 57-60
9. Moss NG, Powell S, Falk RJ. Intravenous cyclosporin activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Sciences USA 1985; 82: 8222-6
10. Kurz A, Bruna RD, Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxta glomerular cells. Kidney Int 1988; 33: 947-53
11. 2 sinthesis induced by cyclosporin-A. Am J Physiol 1986; 251: F584-7
12. Brown Z, Neild GH. Cyclosporine inhibits prostcyclin production by cultured human endothelial cells. Transplant Proc 1987; 19: 1178-80
13. Benigni A, Perico N, Ladny JR, et al. Increased urinary excretion of endothelin-1 and its precursor big-endothelin-1 in rats chronically treated with cyclosporine. Transplantation 1991; 52: 175-7
14. Xue H, Bukoski RD, McCarron DA, et al. Induction of contraction in isolated rat aorta. Transplantation 1987; 43: 715-8
15. Mihatsch MJ, Ryffel B, Gudat F, et al. Cyclosporine nephropathy. In:Tisher CC, Brenner BM, editors. Renal Pathology. Philadelphia: Lippincott, 1989; 1555-86
16. Bennett WM, De Mattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achille's heel of immunosup pressive therapy. Kidney Int 1996; 50: 1089-100
17. Vercauteren SB, Bosmans JL, Elseviers MM, et al. A metaanalysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int 1998; 54: 536-45
18. Zietse R, Wenting GJ, Kramer P, et al. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci 1992; 82: 641-50
19. International Study of Kidney Diseases in Children. Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years of observation. Pediatrics 1984; 73: 497-501
20. Lewis MA, Davis N, Baildom E, et al. Nephrotic syndrome from toddlers to twenties. Lancet 1989; 1: 255-9
21. Schena P, Cameron JS. Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective study. Am J Med 1988; 85: 315-26
22. International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal-change nephrotic syndrome from initial response to prednisone. J Pediatr 1981; 98: 561-4
23. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Lancet 1988; 1: 380-3
24. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Minimal- change nephrotic syndrome (MCNS): long prednisone versus standard prednisone therapy [abstract]. Pediatr Nephrol 1990; 4 C: 60
25. Nolasco F, Cameron J, Heywood EF, et al. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 1986; 29: 1215-23
26. Korbet S, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol 1988; 8: 291-7
27. Simon P, Meyrier A. One-year, alternate day dosage, corticosteroid Rx reduces rate of further relapses in adult minimal change nephrosis [abstract]. Kidney Int 1989; 35: 201
28. Arbeitsgemeinschaft für Paediatrische Nephrologie. Alternate- day versus intermittent prednisone in frequently relapsing nephrotic syndrome. Lancet 1979; I: 401-3
29. Arbeitsgemeinschaft für Paediatrische Nephrologie. Alternate-day prednisone is more effective than intermittent prednisonein frequently relapsing nephrotic syndrome. Eur J Pediatr 1981; 135: 229-37
30. Broyer M, Meyrier A, Niaudet P, et al. Minimal changes and focal segmental glomerular sclerosis. In: Cameron GS, Davison A, Grünfeld JP, et al., editors. Oxford texbook of clinical nephrology. Oxford: Oxford University Press, 1992; 298-339
31. Arbeitsgemeinschaft für Paediatrische Nephrologie. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N England J Med 1982; 306: 451-4
32. th Meeting Am Soc Nephrol 1985; 57A
33. Hoyer PF, Krull F, Brodehl J. Cyclosporine A in frequently relapsing minimal change nephrotic syndrome. Lancet 1986; 11: 692-3
34. Lagrue G, Laurent J, Belghiti D, et al. Cyclosporine A and idiopathic nephrotic sindrome. Lancet 1986; 2: 692-3
35. Meyrier A, Simon P, Perret G, et al. Remission of idiopathic nephrotic sindrome after treatment with cyclosporine A. BMJ 1986; 292: 789-92
36. Capodicasa G, De Santo NG, Nuzzi F, et al. Cyclosporin A in nephrotic sindrome of childhood. A 14 months experience. Int J Pediatr Nephrol 1986; 7: 69-72
37. Tejani A, Butt K, Trachtman H, et al. Cyclosporin A-induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988; 33: 729-34
38. Mentser M, Shannon B, Mahan JD. Cyclosporine treatment of frequently relapsing minimal-change nephrotic syndrome in children. Response to therapy and evidence for a T-cell abnormality [abstract]. Kidney Int 1988; 33: 329
39. Brodehl J, Hoyer PF. Cyclosporin in idiopathic nephrotic syndrome of children. Am J Nephrol 1989; 9 Suppl. 1: 61-4
40. Kitano Y, Yashikawa N, Tanaka R, et al. Cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 1990; 4: 474-7
41. Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol 1991; 35 Suppl. 1: 31S-6S
42. Neuhaus TJ, Burger HR, Klinger M, et al. Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood. Eur J Pediatr 1992; 151: 775-8
43. Tanaka R, Yoshikawa N, Kitano Y, et al. Long-term cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 1993; 7: 249-52
44. Lagrue G, Laurent J, Belghiti D, et al. Cyclosporin and idiopathic nephrotic syndrome. Lancet 1986; II: 692-3
45. Balcke P, Derfler K, Stockenhuber F, et al. Cyclosporin A treatment of patients with minimal-change, nephritis. Wien Klin Wochensehr 1987; 99: 242-5
46. Kuhn K, Futerova M, Brunkhorst R, et al. Cyclosporin A therapy in adult patient with minimal change nephropathy and local sclerosis [abstract]. Nephrol Dial Transplant 1987; 2: 416
47. Clasen W, Kindler J, Mihatsch MJ, et al. Long-term treatment of minimal-change nephrotic syndrome with cyclosporin: a control biopsy study. Nephrol Dial Transplant 1988; 3: 733-7
48. Maher ER, Sweny P, Chappel M, et al. Cyclosporin in the treatment of steroid-responsive and steroid-resistant nephrotic syndrome in adults. Nephrol Dial Transplant 1988; 3: 728-32
49. Meyrier A, Condamin NC, Brooner D, et al. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A. Minimal- change disease and focal-segmental glomerulosclerosis. Clin Nephrol 1991; 35 Suppl. 1: 37S-42S
50. Ittel TH, Clasen W, Fuhs M, et al. Long-term cyclosporin A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin Nephrol 1995; 44: 156-62
51. Tejani A, Suthantiran M, Pomrantz A. A randomized controlled trial of low-dose prednisone and cyclosporin versus high-dose prednisone in nephrotic syndrome in children. Nephron 1991; 33: 729-34
52. Niaudel P, The French Society of Pediatric Nephrology. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Pediatr Nephrol 1992; 6: 1-3
53. Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993; 8: 1326-32
54. Collaborative Study Group of Sandimmun in Nephrotic Syndrome. Safety and tolerability of Cyclosporin A (Sandimmun) in idiopathic nephrotic syndrome. Clin Nephrol 1991; 35 Suppl. 1: 48S-60S
55. Melocoton T, Kamil ES, Cohen AH, et al. Long-term cyclosporin A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis 1991; 18: 583-8
56. Gregory MJ, Smoyer WE, Sedman A, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soe Nephrol 1996; 4: 543-9
57. Holt DW, Mueller EA, Kovarik JM, et al. The pharmacokinetics of sandimmun neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935-9
58. Kahan DB, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low fat meals or high-fat meals. Transplantation 1995; 59: 505-11
59. Beaufils H, Alphonse JC, Guedon J, et al. Focal glomerulosclerosis: natural history and treatment. Nephron 1978; 21: 75-85
60. Cameron JS, Turner DR, Ogg CS, et al. The long-term prognosis of patients with focal and segmental glomerulosclerosis. Clin Nephrol 1978; 10: 211-8
61. Velosa JA, Holley KE, Torres VE, et al. Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 1983; 58: 568-77
62. Korbet SM, Schwartz MM, Lewis EJ. The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine 1986; 63: 304-11
63. Pei Y, Cattran D, Delmore T, et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 1987; 82: 938-44
64. Banfi G, Moriggi M, Sabadini E, et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal segmental glomerulosclerosis with nephrotic syndrome in adults. Clin Nephrol 1991; 36: 53-9
65. Agarwal SK, Dash SC, Tiwari SC, et al. Idiopathic adult focal segmental glomerulosclerosis: a clinicopathological study and response to steroid. Nephron 1993; 63: 168-71
66. Rydel JJ, Korbet SM, Borok RZ, et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to therapy. Am J Kidney Dis 1995; 25: 534-42
67. Tarshish P, Tobin JN, Bernstein J, et al. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1996; 8: 769-76
68. Ponticelli C, Banfi G. Focal and segmental glomerulosclerosis. In: Ponticelli C, Glassoek RJ, editors. Treatment of primary glomerulonephritis. Oxford: Oxford University Press, 1997: 108-45
69. Tarshish P, Tobin JM, Bernstein J, et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Disease in Childhood. Pediatr Nephrol 1996; 10: 590-3
70. Baluarte HJ, Gruskin AB, Polinski MS, et al. Chlorambucil therapy in nephrotic syndrome. In: Gruskin AB, Norman HE, editors. Pediatric Nephrology Proceedings of the 5th International Pediatric Nephrology Symposium. The Hague: Martinus Nijhoff, 1980: 423-9
71. Mendoza SA, Reznik VM, Griswold WR, et al. Treatment of steroid-resistant focal glomerulosclerosis with pulse methyl-prednisolone and alkylating agents. Pediatr Nephrol 1990; 1 (3): 303-7
72. Tune BM, Kirpekar R, Sibley RK, et al. Intravenous methyl- prednisolone and oral alkylating agent therapy of prednisone- resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995; 43: 84-8
73. Waldo FB, Benfield MR, Kohaut EC. Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 1992; 6: 503-7
74. Waldo FB, Kohaut EC. Therapy of focal segmental glomerulosclerosis with Cyclosporin A. Pediatr Nephrol 1987; 1: 180-2
75. Brandis M, Burghard R, Leititis J, et al. Cyclosporin A for treatment of nephrotic syndrome. Transplant Proc 1988; 20 Suppl. 4: 275S-9S
76. James RW, Burke JR, Pertrie JJB, et al. Cyclosporin A in the treatment of childhood glomerulonephritis. Aust NZ J Med 1989; 19: 198-201
77. Ponticelli C, Rizzoni GP, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43: 1377-84
78. Niaudet P, The French Society of Pediatric Nephrology. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediatr 1994; 125: 981-6
79. Ingulli E, Singh A, Baqi N, et al. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 5: 1820-5
80. Hamed RMA. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. J Nephrol 1997; 10: 266-70
81. Hino S, Takemura T, Okada M, et al. Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 1998; 31: 932-9
82. Zietse R, Wentig GJ, Kramer P, et al. Contrasting response to cyclosporin in refractory nephrotic syndrome. Clin Nephrol 1989; 31: 22-5
83. Lee HV, Kim HS, Kang CM, et al. The efficacy of cyclosporin A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea. Clin Nephrol 1995; 43: 375-81
84. Meyrier A, Noël LH, Auriche P, et al. Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994; 45: 1446-56
85. Walker RG, Kineaid-Smith P. The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with cyclosporin. Nephron 1990; 4: 117-21
86. Lieberman KV, Tejani A. A randomized double-blind placebo- controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7: 56-63
87. Miller C, Feutren G, Schiess W, et al. Serum creatinine in cyclosporine-induced remission of steroid resistant nephrotic syndrome. Lancet 1990; II: 1352
88. Habib R, Niaudet P. Comparison between pre- and post-treatment renal biopsies in children receiving cyclosporine for idiopathic nephrosis. Clin Nephrol 1994; 42: 141-6
89. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995; 48 Suppl. 52: S63-S9
90. Mourad G, Vela C, Ribstein J, et al. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998; 65: 661-6
91. Morozumi K, Thiel G, Albert FW, et al. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuance of cyclosporine in renal allografts. Clin Nephrol 1992; 38: 1-8
92. Hogan S, Muller KE, Jennette JC, et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995; 25: 862-75
93. Cattran DC, Pei Y, Greenwood CMT, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901-7
94. Passerini P, Pasquali S, Cesana B, et al. Long-term outcome of patients with membranous nephropathy after complete remission of pioteinuria. Nephrol Dial Transplant 1989; 4: 525-9
95. Lagrue G, Bernard D, Barièty J, et al. Traitement par le chlor ambucil et azathioprine dans les glomérulonéphrites primitives: resultats d'une étude controlée. J Urol Nephrol 1975; 81: 655-72
96. Tiller DJ, Clarkson AR, Mathew T, et al. A prospective randomised trial in the use of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomeruto nephritis. In: Zurukzoglu W, Papadimitriou M, Pyrpasopoulos M, et al, editors. Proceedings of the 8th International Congress of Nephrology. University Studio and Karger, Thessaloniki, 1981: 345-54
97. Murphy BF, McDonald I, Fairley KF, et al. Randomised controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 1992; 37: 229-34
98. Ponticelli C, Passerini P. Alkylating agents and purine analogues in primary glomerulonephritis with nephrotic syndrome. Nephrol Dial Transplant 1991; 6: 381-8
99. Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous glomerulonephritis. N Engl J Med 1984; 310: 945-50
100. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 1600-4
101. Ponticelli C, Zucchelli P, Passerini P, et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 1992; 327; 599-603
102. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methyl prednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-50
103. De Santo NG, Capodicasa G, Giordano C. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am J Nephrol 1987; 1 (7): 74-6
104. Bertoux F, Guerin G, Alamartine E, et al. Traitement par la Cyclosporine A des glomérulonéphrites extramembraneuses primitives avec syndrome néphrotique corticorésistant et persistant (9 cas) [abstract]. Nephrologic 1990; 11: 47
105. Zietse R, Wenting G, Schalekamp M, et al. Effects of cyclosporin on glomerular barrier function in nephrotic syndrome [abstract]. Congress on immuno-intervention in auto-immune disease (CIAD) Paris, 19991 May; 290
106. Meyrier A. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol Dial Transplant 1992; 7 Suppl. 1: 80S-4S
107. Guasch A, Suraniy M, Newton L, et al. Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am J Kidney Dis 1992; 5: 472-81
108. Rostoker G, Belghiti D, Maadi AB, et al. Long-term cyclosporin a therapy for severe idiopathic membranous nephropathy. Nephron 1993; 63: 335-41
109. Ambalavanan S, Fauvel JP, Sibley RK, et al. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996; 1 (7): 290-8
110. Cattran DC, Greenwood C, Ritchie S. A controlled trial of cyclosporin in patients with progressive membranous nephropathy. Kidney Int 1995; 47: 1130-5
111. Fritsche L, Budde K, Färber L, et al. Treatment of membranous glumerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant 1999; 14: 1036-7
112. Ponticelli C, Passerini P. Treatment of the nephrotic syndrome associated with primary glomerulonephritis. Kidney Int 1994; 46: 595-604
113. Ledingham JGG. Immunosuppressive treatment in membranous nephropathy. Q J Med 1990; 274: 117-9
114. Cameron JS. Membranous nepropathy and its treatment. Nephrol Dial Transplant 1992; Suppl. 1 (7): 72-9
115. Hopper J. Prednisolone in the treatment of idiopathic membranous nephropathy [letter]. N Engl J Med 1989; 321: 260
116. Jindal K, West M, Bear R, et al. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 1992; 14: 61-7
117. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992; 326: 1654-60